Paper37814061
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Anagnostou V and 19 others. Nat Med, 2023. Cited by 152 papers, by iCite.
Cite this record
ConductScience Library. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Papers, record 37814061. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37814061
- Disease
- lung cancer261 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
- PubMed
- Publication types
- Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Adaptive Clinical Trial
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Antibodies, Monoclonal, Humanized | |
| Progression-Free Survival |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA121113 | NCI NIH HHS | United States | R01CA121113 | PubMed and NIH |
| CA121113 | NIH HHS | United States | R01CA121113 | PubMed and NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04093167 | Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28864724 | Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28864724 | PubMed |
| 2 | 36350985 | Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. | Sci Transl Med | 2022 | https://conductscience.org/library/papers/36350985 | PubMed |
| 3 | 35764740 | The status of tumor mutational burden and immunotherapy. | Nat Cancer | 2022 | https://conductscience.org/library/papers/35764740 | PubMed |
| 4 | 30541742 | Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. | Cancer Res | 2019 | https://conductscience.org/library/papers/30541742 | PubMed |
| 5 | 35952319 | Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. | JCO Precis Oncol | 2022 | https://conductscience.org/library/papers/35952319 | PubMed |
| 6 | 31488153 | Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. | J Transl Med | 2019 | https://conductscience.org/library/papers/31488153 | PubMed |
| 7 | 29330207 | Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29330207 | PubMed |
| 8 | 31518912 | Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. | Lung Cancer | 2019 | https://conductscience.org/library/papers/31518912 | PubMed |
| 9 | 30013197 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. | Nat Med | 2018 | https://conductscience.org/library/papers/30013197 | PubMed |
| 10 | 30393817 | Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. | Acta Derm Venereol | 2019 | https://conductscience.org/library/papers/30393817 | PubMed |
| 11 | 35121950 | Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. | Nat Cancer | 2020 | https://conductscience.org/library/papers/35121950 | PubMed |
| 12 | 27718847 | Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718847 | PubMed |
| 13 | 29658856 | Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29658856 | PubMed |
| 14 | 36534496 | Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36534496 | PubMed |
| 15 | 34158359 | Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34158359 | PubMed |
| 16 | 30573519 | Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. | Cancer Res | 2019 | https://conductscience.org/library/papers/30573519 | PubMed |
| 17 | 33323406 | The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33323406 | PubMed |
| 18 | 32816849 | Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32816849 | PubMed |
| 19 | 30093454 | Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/30093454 | PubMed |
| 20 | 35688557 | Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35688557 | PubMed |
Cited by127
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953478 | Cellular origins and evolutionary dynamics of plasma cfDNA in solid tumors: integrating germline, tumor-derived, and hematopoietic variation for MRD and treatment guidance. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42953478 | PubMed |
| 42882934 | The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882934 | PubMed |
| 42882836 | Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882836 | PubMed |
| 42871719 | Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42871719 | PubMed |
| 42854587 | Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial. | ESMO Open | 2026 | https://conductscience.org/library/papers/42854587 | PubMed |
| 42824111 | Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions. | Front Oncol | 2026 | https://conductscience.org/library/papers/42824111 | PubMed |
| 42821157 | Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42821157 | PubMed |
| 42807637 | Immune-related biomarkers in liquid biopsy for cancer: emerging tools for non-invasive precision oncology. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42807637 | PubMed |
| 42803873 | Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42803873 | PubMed |
| 42800800 | MammaTrace - a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42800800 | PubMed |
| 42763389 | Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42763389 | PubMed |
| 42694453 | Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow? | Front Immunol | 2026 | https://conductscience.org/library/papers/42694453 | PubMed |
| 42639369 | Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies. | Front Oncol | 2026 | https://conductscience.org/library/papers/42639369 | PubMed |
| 42569325 | Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab ± chemotherapy. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42569325 | PubMed |
| 42568819 | Biomarkers for predicting and monitoring the efficacy of cancer vaccines. | Front Oncol | 2026 | https://conductscience.org/library/papers/42568819 | PubMed |
| 42557506 | Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42557506 | PubMed |
| 42539880 | Targeting tumor transition windows. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42539880 | PubMed |
| 42498740 | Towards liquid biopsy-based analysis of antitumour immunity. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/42498740 | PubMed |
| 42477682 | CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42477682 | PubMed |
| 42416486 | Predictive value of baseline levels and early dynamic changes of ctDNA for 28-day mortality in ICU patients with advanced lung cancer: a prospective single-center cohort study. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42416486 | PubMed |
Genes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PEMBROLIZUMAB | CHEMBL3137343 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3137343 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37814061
GET https://conductscience.org/api/papers/v1/37814061/references?page=2